Sionna Therapeutics 3Q 2026: EPS ($0.72) — 10-Q Summary

Sionna Therapeutics reported a wider net loss of $32.42M in Q3 2026, up 59.9% YoY, due to increased R&D and administrative expenses. The company selected SION-451 + SION-2222 for its dual combination program but will not advance SION-719 after a failed trial. It reduced its workforce by 46% and expects its cash runway to extend into 2H 2029.

Original reporting
Published Nov 10, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sionna Therapeutics 3Q 2026: EPS ($0.72) — 10-Q Summary — source image
Decision brief

The 30-second read

$SIONBearishLow
01

Why it matters

The earnings miss and trial setback are likely to depress the stock in the short term.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; negative catalyst for the stock.

03

What to watch

Potential upside from the dual‑combination program SION-451 + SION-2222 entering Phase 2.

Relevance 8/10Novelty 8/10Timing: after market today

Background

Sionna Therapeutics filed its Q3 2026 10‑Q, reporting widened losses and a failed add‑on trial.

Company-level read

Ticker impact

$SIONBearishHigh confidence
Context

Q3 net loss widened to $32.42M and diluted EPS fell to -$0.72 versus the prior quarter.

Expected impact

downward pressure as investors price in the larger loss and trial failure

Evidence & confidence

Earnings miss and a failed Phase 2a trial are material negative catalysts for a biotech.

Market effects

Biotech sector may see modest pullback as trial failures raise risk perception.

U.S. biotech investors may adjust exposure; limited broader market effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

The restructuring and cash runway to 2029 could support a longer‑term rebound.

Key entities

  • Sionna Therapeutics

    Biotech firm reporting Q3 2026 results.

Related articles

$SIONMed

Sionna Therapeutics Reports Third Quarter 2026 Financial Results

Sionna Therapeutics, Inc. (SION) filed an SEC Form 8-K — Results of Operations and Financial Condition. Sionna Therapeutics Reports Third Quarter 2026 Financial Results Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027 Clinical and nonclinical data presented at 2026 NACFC support advance

$SIONMedAI 8/10

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Sionna Therapeutics (Nasdaq: SION) will present data at the 2026 North American Cystic Fibrosis Conference. The company reported post hoc analyses of the PreciSION CF trial, showing an 8.6 mmol/L sweat chloride reduction with SION-719. Sionna plans to advance SION-451 + SION-2222 into a Phase 2a trial in early 2027. Preclinical data suggests potential benefits for a broad CF population.

$RAREMed

Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead

Ultragenyx (RARE) gained FDA approval for FAYUVI, a treatment for Sanfilippo syndrome Type A, closing at $14.50, up 12.58%. Nuvation Bio (NUVB) expanded IBTROZI's label with new lung cancer data, closing at $6.07, up 5.02%. Bayer (BAYRY) won FDA approval for Kerendia in type 1 diabetes-related CKD, closing at $14.13, up 0.57%. Biogen (BIIB) and Eisai (ESALY.PK) received Japan approval for LEQEMBI Pen, closing at $219.05, up 1.41%. Telix (TLX) got FDA approval for Pixclara, a PET imaging agent fo

$VRTXMedAI 8/10

Vertex Pharmaceuticals' Rally Has a New Engine

Vertex Pharmaceuticals (VRTX) maintains dominance in the cystic fibrosis (CF) drug market. Sionna Therapeutics (SION) reported a clinical trial failure for SION-719, causing its stock to drop 90%. Analysts see this as a positive for Vertex, which has expanded its CF portfolio and launched new drugs in other areas, such as Casgevy for rare blood diseases. Vertex's strong position and diversification make it an attractive investment, according to analysts.